BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hedlin P, Taschuk R, Potter A, Griebel P, Napper S. Detection and control of prion diseases in food animals. ISRN Vet Sci 2012;2012:254739. [PMID: 23738120 DOI: 10.5402/2012/254739] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
Number Citing Articles
1 Murugesan C, Manivannan P, Gangatharan M. Pros and cons in prion diseases abatement: Insights from nanomedicine and transmissibility patterns. Int J Biol Macromol 2020;145:21-7. [PMID: 31866542 DOI: 10.1016/j.ijbiomac.2019.12.150] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
2 Spizzo T, Denner J, Gazda L, Martin M, Nathu D, Scobie L, Takeuchi Y. First update of the International Xenotransplantation Association consensus statement on conditions for undertaking clinical trials of porcine islet products in type 1 diabetes-Chapter 2a: source pigs-preventing xenozoonoses. Xenotransplantation 2016;23:25-31. [DOI: 10.1111/xen.12223] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 5.8] [Reference Citation Analysis]
3 Gong JS, Li W, Zhang DD, Xie MF, Yang B, Zhang RX, Li H, Lu ZM, Xu ZH, Shi JS. Biochemical Characterization of An Arginine-Specific Alkaline Trypsin from Bacillus licheniformis. Int J Mol Sci 2015;16:30061-74. [PMID: 26694369 DOI: 10.3390/ijms161226200] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
4 Taschuk R, Marciniuk K, Määttänen P, Madampage C, Hedlin P, Potter A, Lee J, Cashman NR, Griebel PJ, Napper S. Safety, specificity and immunogenicity of a PrP(Sc)-specific prion vaccine based on the YYR disease specific epitope. Prion 2014;8:51-9. [PMID: 24509522 DOI: 10.4161/pri.27962] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
5 Marciniuk K, Taschuk R, Napper S. Evidence for prion-like mechanisms in several neurodegenerative diseases: potential implications for immunotherapy. Clin Dev Immunol 2013;2013:473706. [PMID: 24228054 DOI: 10.1155/2013/473706] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 2.7] [Reference Citation Analysis]
6 Madampage CA, Määttänen P, Marciniuk K, Brownlie R, Andrievskaia O, Potter A, Cashman NR, Lee JS, Napper S. Binding of bovine T194A PrP(C) by PrP(Sc)-specific antibodies: potential implications for immunotherapy of familial prion diseases. Prion 2013;7:301-11. [PMID: 23787697 DOI: 10.4161/pri.25148] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]